Pub Date : 2019-01-01Epub Date: 2019-04-22DOI: 10.1016/bs.podrm.2018.11.001
Fulwah Yahya Alqahtani, Fadilah Sfouq Aleanizy, Eram El Tahir, Hamad M Alkahtani, Bushra T AlQuadeib
Paclitaxel is the first microtubule-stabilizing agent identified and considered to be the most significant advance in chemotherapy of the past two decades. It is considered one of the most widely used antineoplastic agents with broad activity in several cancers including breast cancer, endometrial cancer, non-small-cell lung cancer, bladder cancer, and cervical carcinoma. It is also used for treating AIDS-related Kaposi sarcoma as a second line treatment. This comprehensive profile of paclitaxel gives overview of nomenclature, formulae, elemental analysis, appearance, application and uses. In addition, mechanism of action and resistance, different dosage forms and methods of drug preparation are elaborated. Moreover, the physicochemical properties involving X-ray powder diffraction pattern, drug solubility, melting point, differential scanning calorimetry, and stability were summarized. Furthermore, method of drug analysis including compendial, spectrophotometric, and chromatographic was discussed.
{"title":"Paclitaxel.","authors":"Fulwah Yahya Alqahtani, Fadilah Sfouq Aleanizy, Eram El Tahir, Hamad M Alkahtani, Bushra T AlQuadeib","doi":"10.1016/bs.podrm.2018.11.001","DOIUrl":"https://doi.org/10.1016/bs.podrm.2018.11.001","url":null,"abstract":"<p><p>Paclitaxel is the first microtubule-stabilizing agent identified and considered to be the most significant advance in chemotherapy of the past two decades. It is considered one of the most widely used antineoplastic agents with broad activity in several cancers including breast cancer, endometrial cancer, non-small-cell lung cancer, bladder cancer, and cervical carcinoma. It is also used for treating AIDS-related Kaposi sarcoma as a second line treatment. This comprehensive profile of paclitaxel gives overview of nomenclature, formulae, elemental analysis, appearance, application and uses. In addition, mechanism of action and resistance, different dosage forms and methods of drug preparation are elaborated. Moreover, the physicochemical properties involving X-ray powder diffraction pattern, drug solubility, melting point, differential scanning calorimetry, and stability were summarized. Furthermore, method of drug analysis including compendial, spectrophotometric, and chromatographic was discussed.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/bs.podrm.2018.11.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37366646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-01Epub Date: 2019-01-18DOI: 10.1016/bs.podrm.2018.11.003
Ahmed A Abdelgalil, Hamad M Alkahtani, Fahad I Al-Jenoobi
Sorafenib (BAY-43-9006), marketed by Bayer as Nexavar® (USA), is anticancer drug approved by US-FDA for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma. Sorafenib inhibited tumor growth and angiogenesis through targeting both the RAF/MEK/ERK pathway and receptor tyrosine kinases. This study presents a comprehensive profile of sorafenib, including detailed nomenclature, formula, elemental analysis, methods of preparation, physico-chemical characteristics, and methods of analysis (including spectroscopic, electrochemical, and chromatographic methods of analysis). Spectroscopic and spectrometric analyses include UV/vis spectroscopy, vibrational spectroscopy, nuclear magnetic resonance spectrometry ((1)H and (13)C NMR), and mass spectrometry. Chromatographic methods of analyses include thin layer chromatography and high-performance liquid chromatography. Only few stability indicating methods were found for quantification of sorafenib after exposing tablet dosage form to various stress conditions such as hydrolysis, oxidation, thermal stress, photo and UV light. However, none of these described methods were made to separate and quantify the degradation products. Pharmacology studies including pharmacodynamics, mechanism of action, pharmacokinetics and drug-drug interactions were also presented. An appropriate table and figures were attached to each of the above mentioned sections along with total of 55 references.
{"title":"Sorafenib.","authors":"Ahmed A Abdelgalil, Hamad M Alkahtani, Fahad I Al-Jenoobi","doi":"10.1016/bs.podrm.2018.11.003","DOIUrl":"https://doi.org/10.1016/bs.podrm.2018.11.003","url":null,"abstract":"<p><p>Sorafenib (BAY-43-9006), marketed by Bayer as Nexavar® (USA), is anticancer drug approved by US-FDA for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma. Sorafenib inhibited tumor growth and angiogenesis through targeting both the RAF/MEK/ERK pathway and receptor tyrosine kinases. This study presents a comprehensive profile of sorafenib, including detailed nomenclature, formula, elemental analysis, methods of preparation, physico-chemical characteristics, and methods of analysis (including spectroscopic, electrochemical, and chromatographic methods of analysis). Spectroscopic and spectrometric analyses include UV/vis spectroscopy, vibrational spectroscopy, nuclear magnetic resonance spectrometry ((1)H and (13)C NMR), and mass spectrometry. Chromatographic methods of analyses include thin layer chromatography and high-performance liquid chromatography. Only few stability indicating methods were found for quantification of sorafenib after exposing tablet dosage form to various stress conditions such as hydrolysis, oxidation, thermal stress, photo and UV light. However, none of these described methods were made to separate and quantify the degradation products. Pharmacology studies including pharmacodynamics, mechanism of action, pharmacokinetics and drug-drug interactions were also presented. An appropriate table and figures were attached to each of the above mentioned sections along with total of 55 references.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/bs.podrm.2018.11.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37366647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-01DOI: 10.1016/s1871-5125(19)30011-1
{"title":"Contributors","authors":"","doi":"10.1016/s1871-5125(19)30011-1","DOIUrl":"https://doi.org/10.1016/s1871-5125(19)30011-1","url":null,"abstract":"","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/s1871-5125(19)30011-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56842749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-01Epub Date: 2019-03-08DOI: 10.1016/bs.podrm.2019.02.002
William Craig Stagner, Shalini Gaddam, Rudrangi Parmar, Ajay Kumar Ghanta
Sucrose octaacetate (SOA) is a United States National Formulary (NF) monograph compendial material (U.S. Pharmacopeia, 2008), and, as shown in Fig. 1, has eight acetate groups attached to a sucrose moiety. It is a natural product that has been extracted from the seeds of Annona cornifolia (Lima et al., 2011). It is nontoxic (Sigma-Aldrich, 2016) and has a number of uses based on its bitter taste. For example, sugar is rendered too bitter is eat at a concentration of 0.06% (w/w) SOA (Mann et al., 1992). SOA can form 255 different possible isomers and degradation products, all of which have a very low molar absorptivity. Its ultraviolet molar absorptivity at 210nm has been reported to be 439 absorption units/cm/M in water and 442 absorption units/cm/M in 30:70 acetonitrile-water.
八乙酸蔗糖(SOA)是美国国家处方(NF)专著药典材料(美国药典,2008),如图1所示,有八个醋酸基团连接到蔗糖部分。它是一种天然产品,从金叶番荔枝种子中提取(Lima et al., 2011)。它是无毒的(Sigma-Aldrich, 2016),并且基于它的苦味有许多用途。例如,当糖的浓度为0.06% (w/w) SOA时,糖会变得太苦(Mann et al., 1992)。SOA可以形成255种不同的异构体和降解产物,它们都具有非常低的摩尔吸收率。其在210nm处的紫外摩尔吸收率在水中为439个吸收单位/cm/M,在30:70的乙腈水中为442个吸收单位/cm/M。
{"title":"Sucrose octaacetate.","authors":"William Craig Stagner, Shalini Gaddam, Rudrangi Parmar, Ajay Kumar Ghanta","doi":"10.1016/bs.podrm.2019.02.002","DOIUrl":"https://doi.org/10.1016/bs.podrm.2019.02.002","url":null,"abstract":"<p><p>Sucrose octaacetate (SOA) is a United States National Formulary (NF) monograph compendial material (U.S. Pharmacopeia, 2008), and, as shown in Fig. 1, has eight acetate groups attached to a sucrose moiety. It is a natural product that has been extracted from the seeds of Annona cornifolia (Lima et al., 2011). It is nontoxic (Sigma-Aldrich, 2016) and has a number of uses based on its bitter taste. For example, sugar is rendered too bitter is eat at a concentration of 0.06% (w/w) SOA (Mann et al., 1992). SOA can form 255 different possible isomers and degradation products, all of which have a very low molar absorptivity. Its ultraviolet molar absorptivity at 210nm has been reported to be 439 absorption units/cm/M in water and 442 absorption units/cm/M in 30:70 acetonitrile-water.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/bs.podrm.2019.02.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37191229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-01Epub Date: 2019-01-14DOI: 10.1016/bs.podrm.2018.11.005
Nasr Y Khalil, Haitham K AlRabiah, Saad S Al Rashoud, Ahmed Bari, Tanveer A Wani
Topiramate, 2,3:4,5-di-O-isopropylidene-β-d-fructopyranose sulfamate, is a potent antiepileptic drug with a broad spectrum of activity. It is effective in both partial and generalized seizures. Topiramate was also found to have significant efficacy in migraine prevention with considerable reductions in the frequency of migraine headaches. The most common adverse events, which may accompany the use of topiramate, are paresthesia, fatigue, decreased appetite, nausea, diarrhea, weight decrease and taste perversion. The weight loss observed with the use of topiramate in obese, epileptic patients, afforded the approval of this drug as an anti-obesity medication. This action is thought to be based on the selective inhibition of mitochondrial carbonic anhydrase isoforms. This profile is prepared to discuss and explain physical characteristics, proprietary and nonproprietary names of topiramate. It also includes methods of preparation, thermal and spectral behavior and methods of analysis. Pharmacokinetics, metabolism, excretion and pharmacology together with its uses and applications are also discussed.
托吡酯(2,3:4,5-二- o -异丙基-β-d-果糖氨基磺酸)是一种具有广谱活性的有效抗癫痫药物。它对部分性和全身性癫痫发作都有效。托吡酯在预防偏头痛方面也有显著的疗效,可以显著降低偏头痛的发生频率。最常见的不良事件,可能伴随使用托吡酯,是感觉异常,疲劳,食欲下降,恶心,腹泻,体重减轻和味觉变态。在肥胖、癫痫患者中使用托吡酯观察到的体重减轻,给予了这种药物作为抗肥胖药物的批准。这种作用被认为是基于选择性抑制线粒体碳酸酐酶同工型。本简介旨在讨论和解释托吡酯的物理特性、专有和非专有名称。它还包括制备方法,热和光谱行为和分析方法。并讨论了其药代动力学、代谢、排泄和药理学及其用途和应用。
{"title":"Topiramate: Comprehensive profile.","authors":"Nasr Y Khalil, Haitham K AlRabiah, Saad S Al Rashoud, Ahmed Bari, Tanveer A Wani","doi":"10.1016/bs.podrm.2018.11.005","DOIUrl":"https://doi.org/10.1016/bs.podrm.2018.11.005","url":null,"abstract":"<p><p>Topiramate, 2,3:4,5-di-O-isopropylidene-β-d-fructopyranose sulfamate, is a potent antiepileptic drug with a broad spectrum of activity. It is effective in both partial and generalized seizures. Topiramate was also found to have significant efficacy in migraine prevention with considerable reductions in the frequency of migraine headaches. The most common adverse events, which may accompany the use of topiramate, are paresthesia, fatigue, decreased appetite, nausea, diarrhea, weight decrease and taste perversion. The weight loss observed with the use of topiramate in obese, epileptic patients, afforded the approval of this drug as an anti-obesity medication. This action is thought to be based on the selective inhibition of mitochondrial carbonic anhydrase isoforms. This profile is prepared to discuss and explain physical characteristics, proprietary and nonproprietary names of topiramate. It also includes methods of preparation, thermal and spectral behavior and methods of analysis. Pharmacokinetics, metabolism, excretion and pharmacology together with its uses and applications are also discussed.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/bs.podrm.2018.11.005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37191231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-01Epub Date: 2019-04-16DOI: 10.1016/bs.podrm.2019.02.001
Gamal A E Mostafa, Yazeed H Al-Otaibi, Abdullah A Al-Badr
A comprehensive profile of cefpodoxime proxetil including the nomenclatures, formulae, elemental composition, appearance, uses, and applications. The methods which were developed for the preparation of the drug substance and their respective schemes are outlined. The physical characteristics of the drug including the ionization constant, solubility, X-ray powder diffraction pattern, differential scanning calorimetry, thermal behavior, and spectroscopic studies are included. The methods which were used for the analysis of the drug substance in bulk drug and/or in pharmaceutical formulations includes the compendial, spectrophotometric, electrochemical and the chromatographic methods. The other studies which was carried out on this drug substance are including the drug stability, pharmacokinetics, bioavailability, drug evaluation, comparison and several compiled reviews. Finally, more than two hundred references are listed at the end of this profile.
{"title":"Cefpodoxime proxetil.","authors":"Gamal A E Mostafa, Yazeed H Al-Otaibi, Abdullah A Al-Badr","doi":"10.1016/bs.podrm.2019.02.001","DOIUrl":"10.1016/bs.podrm.2019.02.001","url":null,"abstract":"<p><p>A comprehensive profile of cefpodoxime proxetil including the nomenclatures, formulae, elemental composition, appearance, uses, and applications. The methods which were developed for the preparation of the drug substance and their respective schemes are outlined. The physical characteristics of the drug including the ionization constant, solubility, X-ray powder diffraction pattern, differential scanning calorimetry, thermal behavior, and spectroscopic studies are included. The methods which were used for the analysis of the drug substance in bulk drug and/or in pharmaceutical formulations includes the compendial, spectrophotometric, electrochemical and the chromatographic methods. The other studies which was carried out on this drug substance are including the drug stability, pharmacokinetics, bioavailability, drug evaluation, comparison and several compiled reviews. Finally, more than two hundred references are listed at the end of this profile.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/bs.podrm.2019.02.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37366644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-01DOI: 10.1016/S1871-5125(19)30012-3
Harry G. Brittain
{"title":"Preface.","authors":"Harry G. Brittain","doi":"10.1016/S1871-5125(19)30012-3","DOIUrl":"https://doi.org/10.1016/S1871-5125(19)30012-3","url":null,"abstract":"","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76266945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-01Epub Date: 2019-03-25DOI: 10.1016/bs.podrm.2019.02.003
Haitham Alrabiah
A comprehensive profile of levetiracetam is presented in this chapter which includes its description, formula, elemental analysis, appearance, uses and applications. Different earlier studies included for example methods of synthesis are described with its typical structural schemes. The profile also listed the drug's physical characteristics indicating its solubility, X-ray powder diffraction pattern, thermal methods of analysis as well as its spectroscopic characteristics. Different methods of analysis which includes compendial method of analysis, as well as reported method of analysis which include spectrophotometry, spectrofluorometry, electrochemical method, chromatographic method, and immunoassay method of analysis. The study was include drug stability, clinical pharmacology, e.g., mechanism of action, pharmacokinetic study. Around 70 references are recorded as a proof of this chapter.
{"title":"Levetiracetam.","authors":"Haitham Alrabiah","doi":"10.1016/bs.podrm.2019.02.003","DOIUrl":"https://doi.org/10.1016/bs.podrm.2019.02.003","url":null,"abstract":"<p><p>A comprehensive profile of levetiracetam is presented in this chapter which includes its description, formula, elemental analysis, appearance, uses and applications. Different earlier studies included for example methods of synthesis are described with its typical structural schemes. The profile also listed the drug's physical characteristics indicating its solubility, X-ray powder diffraction pattern, thermal methods of analysis as well as its spectroscopic characteristics. Different methods of analysis which includes compendial method of analysis, as well as reported method of analysis which include spectrophotometry, spectrofluorometry, electrochemical method, chromatographic method, and immunoassay method of analysis. The study was include drug stability, clinical pharmacology, e.g., mechanism of action, pharmacokinetic study. Around 70 references are recorded as a proof of this chapter.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/bs.podrm.2019.02.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37366645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-01Epub Date: 2018-12-21DOI: 10.1016/bs.podrm.2018.11.002
Iqbal Ahmad, Muhammad Ali Sheraz, Sofia Ahmed, Zubair Anwar
Pharmaceutical preparations may contain a single ingredient or multi-ingredients as well as excipients. In multicomponent systems, specific analytical methods are required to determine the concentrations of individual components in the presence of interfering substances. Ultraviolet and visible spectrometric methods have widely been developed for the analysis of drugs in mixtures and pharmaceutical preparations. These methods are based on ultraviolet and visible multicomponent analysis and chemometrics (multivariate data analysis). The commonly used chemometric methods include principal component analysis (PCA); regression involving classical least squares (CLS), partial least squares (PLS), inverse least squares (ILS), principal component regression (PCR), multiple linear regression (MLR), artificial neural networks (ANNs); soft independent modeling of class anthology (SIMCA), PLS-discriminant analysis (DA); and functional data analysis (FDA). In this chapter, the applications of multicomponent ultraviolet and visible, derivative, infrared and mass spectrometric and spectrofluorimetric methods to the analysis of multi-ingredient pharmaceutical preparations, biological samples and the kinetics of drug degradation have been reviewed. Chemometric methods provide an efficient solution to calibration problems in the analysis of spectral data for the simultaneous determination of drugs in multicomponent systems. These methods facilitate the assessment of product quality and enhance the efficiency of quality control systems.
{"title":"Multicomponent spectrometric analysis of drugs and their preparations.","authors":"Iqbal Ahmad, Muhammad Ali Sheraz, Sofia Ahmed, Zubair Anwar","doi":"10.1016/bs.podrm.2018.11.002","DOIUrl":"https://doi.org/10.1016/bs.podrm.2018.11.002","url":null,"abstract":"<p><p>Pharmaceutical preparations may contain a single ingredient or multi-ingredients as well as excipients. In multicomponent systems, specific analytical methods are required to determine the concentrations of individual components in the presence of interfering substances. Ultraviolet and visible spectrometric methods have widely been developed for the analysis of drugs in mixtures and pharmaceutical preparations. These methods are based on ultraviolet and visible multicomponent analysis and chemometrics (multivariate data analysis). The commonly used chemometric methods include principal component analysis (PCA); regression involving classical least squares (CLS), partial least squares (PLS), inverse least squares (ILS), principal component regression (PCR), multiple linear regression (MLR), artificial neural networks (ANNs); soft independent modeling of class anthology (SIMCA), PLS-discriminant analysis (DA); and functional data analysis (FDA). In this chapter, the applications of multicomponent ultraviolet and visible, derivative, infrared and mass spectrometric and spectrofluorimetric methods to the analysis of multi-ingredient pharmaceutical preparations, biological samples and the kinetics of drug degradation have been reviewed. Chemometric methods provide an efficient solution to calibration problems in the analysis of spectral data for the simultaneous determination of drugs in multicomponent systems. These methods facilitate the assessment of product quality and enhance the efficiency of quality control systems.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/bs.podrm.2018.11.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37191232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-01DOI: 10.1016/s1871-5125(19)30007-x
{"title":"Series Page","authors":"","doi":"10.1016/s1871-5125(19)30007-x","DOIUrl":"https://doi.org/10.1016/s1871-5125(19)30007-x","url":null,"abstract":"","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/s1871-5125(19)30007-x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56842631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}